Bill > HR4127

This bill, the Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021, aims to encourage the development and use of DISARM antimicrobial drugs. It provides for additional Medicare payments to hospitals for using these drugs, which are approved by the FDA, designated as qualified infectious disease products, and have received exclusivity extensions. The bill also authorizes $500 million in funding for the Centers for Disease Control and Prevention to support antimicrobial stewardship programs and data reporting capabilities, particularly in rural and community hospitals. Additionally, the bill requires a 5-year study by the Government Accountability Office to examine barriers to the development of DISARM antimicrobial drugs, including patient outcomes, the effectiveness of stewardship programs, and implications for Medicare payment reform.

Budget and Finance, Health and Social Services

https://www.congress.gov/bill/117th-congress/house-bill/4127/all-info